Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBT (2022 - 2026)

Axsome Therapeutics' EBT history spans 5 years, with the latest figure at -$64.5 million for Q1 2026.

  • On a quarterly basis, EBT fell 8.63% to -$64.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$188.8 million, a 32.12% increase, with the full-year FY2025 number at -$183.7 million, up 36.02% from a year prior.
  • EBT hit -$64.5 million in Q1 2026 for Axsome Therapeutics, down from -$28.1 million in the prior quarter.
  • Over the last five years, EBT for AXSM hit a ceiling of -$8.6 million in Q1 2023 and a floor of -$99.0 million in Q4 2023.
  • Historically, EBT has averaged -$56.5 million across 5 years, with a median of -$61.2 million in 2022.
  • Biggest five-year swings in EBT: skyrocketed 78.2% in 2023 and later tumbled 691.35% in 2024.
  • Tracing AXSM's EBT over 5 years: stood at -$61.2 million in 2022, then plummeted by 61.62% to -$99.0 million in 2023, then grew by 24.4% to -$74.8 million in 2024, then soared by 62.41% to -$28.1 million in 2025, then tumbled by 129.45% to -$64.5 million in 2026.
  • Business Quant data shows EBT for AXSM at -$64.5 million in Q1 2026, -$28.1 million in Q4 2025, and -$47.2 million in Q3 2025.